These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 10460052)

  • 1. Treatment of hepatitis C: a decision that needs careful consideration.
    Wright TL
    Am J Med; 1999 Aug; 107(2):180-1. PubMed ID: 10460052
    [No Abstract]   [Full Text] [Related]  

  • 2. [Diagnosis, treatment, and follow-up of hepatitis C-virus related liver disease. Hungarian national consensus guideline].
    Hunyady B; Gervain J; Horváth G; Makara M; Pár A; Szalay F; Telegdy L; Tornai I
    Orv Hetil; 2014 Mar; 155 Suppl():3-24. PubMed ID: 24631886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Introduction: combination antiviral therapy in chronic hepatitis C.
    Sherlock S
    J Hepatol; 1995; 23 Suppl 2():1-2. PubMed ID: 8720285
    [No Abstract]   [Full Text] [Related]  

  • 4. The treatment of hepatitis C.
    Sievert W; Batey RG
    Med J Aust; 1999 Mar; 170(5):200-2. PubMed ID: 10092915
    [No Abstract]   [Full Text] [Related]  

  • 5. Is treatment failure for hepatitis C virus infection in HIV-positive drug users associated with a shift in HCV genotypes?
    Soriano V; Pérez-Olmeda M; Ríos P; Núñez M; García-Samaniego J; González-Lahoz J
    J Acquir Immune Defic Syndr; 2003 Apr; 32(4):465-6. PubMed ID: 12640209
    [No Abstract]   [Full Text] [Related]  

  • 6. [Genotype 1 superresponder treat for only 24 weeks].
    MMW Fortschr Med; 2005 Dec; 147(51-52):69. PubMed ID: 16402717
    [No Abstract]   [Full Text] [Related]  

  • 7. Hepatitis C treatment outcomes using interferon- and ribavirin-based therapy in Kigali, Rwanda.
    Riedel DJ; Taylor S; Simango R; Kiromera A; Sebeza J; Baribwira C; Musabeyezu E
    Trans R Soc Trop Med Hyg; 2016 Aug; 110(8):495-7. PubMed ID: 27618922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Virus factors determining the outcome of IFN treatment for chronic hepatitis C].
    Kanazawa N; Nakagawa M; Watanabe H; Sakamoto N; Enomoto N
    Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):474-80. PubMed ID: 15359844
    [No Abstract]   [Full Text] [Related]  

  • 9. [Evaluating the efficacy of interferon therapy on hepatitis C patients].
    Shiraha H; Iwasaki Y; Shiratori Y
    Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):489-92. PubMed ID: 15359847
    [No Abstract]   [Full Text] [Related]  

  • 10. What is the role of sofosbuvir in treating hepatitis C infection?
    Carey L
    JAAPA; 2015 Feb; 28(2):16-9. PubMed ID: 25621961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of hepatitis C. Different modalities based on viral genotype].
    Pariente A
    Rev Prat; 2003 Jun; 53(11):1175-6. PubMed ID: 15185639
    [No Abstract]   [Full Text] [Related]  

  • 12. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C.
    Abdelmalek MF; Firpi RJ; Soldevila-Pico C; Reed AI; Hemming AW; Liu C; Crawford JM; Davis GL; Nelson DR
    Liver Transpl; 2004 Feb; 10(2):199-207. PubMed ID: 14762857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meta-analysis: re-treatment of genotype I hepatitis C nonresponders and relapsers after failing interferon and ribavirin combination therapy.
    Singal AG; Waljee AK; Shiffman M; Bacon BR; Schoenfeld PS
    Aliment Pharmacol Ther; 2010 Oct; 32(8):969-83. PubMed ID: 20937042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prompt arrival of antivirals against hepatitis C for HIV patients.
    Barreiro P; Vispo E
    AIDS Rev; 2010; 12(4):242-3. PubMed ID: 21344779
    [No Abstract]   [Full Text] [Related]  

  • 15. Interferon/pegylated interferon and ribavirin in HCV-associated kidney disease with or without cryoglobulinemia.
    Bruchfeld A; Lindahl K; Stahle L; Schvarcz R
    J Hepatol; 2006 Feb; 44(2):432-3; author reply 433. PubMed ID: 16338023
    [No Abstract]   [Full Text] [Related]  

  • 16. Management of hepatitis C virus genotype 4.
    Abdo AA; Lee SS
    J Gastroenterol Hepatol; 2004 Nov; 19(11):1233-9. PubMed ID: 15482528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of hepatitis C.
    Satoor S; Raufman JP
    Clin Cornerstone; 2001; 3(6):37-46. PubMed ID: 11501193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.
    Akuta N; Suzuki F; Sezaki H; Suzuki Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Watahiki S; Sato J; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2006 Jan; 78(1):83-90. PubMed ID: 16299715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment duration for genotypes 2 and 3: still confusing after all these years.
    Jensen DM
    J Clin Gastroenterol; 2010 Sep; 44(8):527-8. PubMed ID: 20628314
    [No Abstract]   [Full Text] [Related]  

  • 20. Infection fighters. Hepatitis C--is a cure possible?
    TreatmentUpdate; 2005; 17(1):8-9. PubMed ID: 17225319
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.